Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

This study has been completed.
Celgene Corporation
Information provided by (Responsible Party):
Pancreatic Cancer Research Team Identifier:
First received: February 14, 2011
Last updated: June 15, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2015
  Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)